Associated tags: Patient safety, Potyvirus, Cancer, Oncology, Health, Biotechnology, Pharmaceutical, Research, Stem Cells, Northwest Biotherapeutics, Patient, Pharmaceutical industry, Science, Clinical Trials, NYSE, Vaccine, Supernova, Neoplasm, General Health
Locations: III, UNITED STATES, NORTH AMERICA, CALIFORNIA, CHICAGO, ILLINOIS, CITY OF HOPE
Oncology,
Health,
Stem Cells,
Clinical Trials,
Pharmaceutical,
Biotechnology,
ASCO,
Abstract,
Annual general meeting,
City,
Dove Medical Press,
Publication,
Society Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the acceptance of three abstracts that will be presented in a poster session at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 31-June 4, 2024, in Chicago, Illinois.
Key Points:
- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the acceptance of three abstracts that will be presented in a poster session at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 31-June 4, 2024, in Chicago, Illinois.
- The posters will include an update from a City of Hope-led Phase 1 study of Calidi's CLD-101 program, focusing on the treatment of recurrent high-grade glioma, now advancing into its fourth cohort of participants.
- CLD-101 is a cutting-edge therapeutic candidate in Calidi’s NeuroNova program, comprising tumor-tropic neural stem cells (NSCs) that deliver an oncolytic adenovirus – CRAd-S-pk7 – selectively to tumor sites.
- Poster Title: Non-clinical evidence supporting the upcoming CLD-201 clinical trial: Cell-based oncolytic virotherapy for multiple solid tumors
Copies of the posters will be available on the Publications section of Calidi’s website following presentation at the meeting.
Calidi Biotherapeutics Inc. (NYSE American: CLDI), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, is pleased to invite investors to a webinar on April 24, 2024 at 4:15 p.m.
Key Points:
- Calidi Biotherapeutics Inc. (NYSE American: CLDI), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, is pleased to invite investors to a webinar on April 24, 2024 at 4:15 p.m.
- The exclusive event, hosted by RedChip Companies, will feature Calidi Biotherapeutics Chief Business Officer, Stephen Thesing, Chief Scientific Officer, Antonio F. Santidrian, Ph.D., and Chief Financial Officer, Andrew Jackson, who will share insight into the Company’s proprietary technology platforms and current development pipeline.
- A live Q&A session will follow the presentation.
- To register for the free webinar, please visit: https://redchip.zoom.us/webinar/register/WN_qT-PBRbTQ0yLeBbJ4jzPSw#/regi...
Questions can be pre-submitted to [email protected] or online during the live event.
Biotechnology,
Pharmaceutical,
Health,
Oncology,
4th floor,
Sale,
Prospectus,
Ladenburg Thalmann,
Security (finance),
Warrant,
Form,
Venture round,
Fifth Avenue,
Series,
Telephone The common warrants will have an exercise price of $0.60 per share, and the Series A Common Warrants, Series B Unit Warrant and Series C Unit Warrant will be exercisable immediately.
Key Points:
- The common warrants will have an exercise price of $0.60 per share, and the Series A Common Warrants, Series B Unit Warrant and Series C Unit Warrant will be exercisable immediately.
- The Company intends to use the net proceeds of the offering for working capital and general corporate purposes, and pre-clinical and clinical trials, as well as the repayment of certain debt.
- Ladenburg Thalmann & Co. Inc. acted as the sole placement agent of the offering.
- The securities described above are being offered pursuant to a registration statement on Form S-1, as amended, (File No.
Oncology,
Health,
Stem Cells,
Clinical Trials,
Research,
Science,
Biotechnology,
4th floor,
Sale,
Prospectus,
Ladenburg Thalmann,
Security (finance),
Warrant,
Form,
Venture round,
Fifth Avenue,
Series,
Telephone The common warrants will have an exercise price of $0.60 per share, and the Series A Common Warrants, Series B Unit Warrant and Series C Unit Warrant will be exercisable immediately.
Key Points:
- The common warrants will have an exercise price of $0.60 per share, and the Series A Common Warrants, Series B Unit Warrant and Series C Unit Warrant will be exercisable immediately.
- The closing of the offering is expected to occur on or about April 18, 2024, subject to the satisfaction of customary closing conditions.
- Ladenburg Thalmann & Co. Inc. is acting as sole placement agent in connection with the offering.
- The offering is being made only by means of a prospectus forming part of the effective registration statement.
Research,
Genetics,
Clinical Trials,
Biotechnology,
General Health,
Pharmaceutical,
Health,
Science,
Oncology,
Other Science,
B cell,
Immunity,
Cell,
Patient,
City,
Tumor microenvironment,
Cancer,
AACR,
Chemokine,
Clinical trial,
Immune system,
Virus,
Potyvirus,
Poster,
Vaccine The poster, titled “Deciphering anticancer mechanisms of oncolytic virus-loaded stem cells,” will be presented on April 9, 2024, during the Chemotherapy, Radiation, and Vaccine Mediated Immunity session.
Key Points:
- The poster, titled “Deciphering anticancer mechanisms of oncolytic virus-loaded stem cells,” will be presented on April 9, 2024, during the Chemotherapy, Radiation, and Vaccine Mediated Immunity session.
- “Calidi’s novel approach to treating cancer has always centered around the stem cell as a means of protecting, delivering, and potentiating our tumor-killing virotherapeutic payloads.
- In the studies presented at AACR, scientists at Calidi Biotherapeutics and City of Hope researched the stem cells secretome transcriptomic of CLD-101 and CLD-201.
- This poster will be posted to the “Scientific Publications” section of the Calidi Biotherapeutics website following the conclusion of the conference.
Science,
Stem Cells,
Biotechnology,
Research,
Pharmaceutical,
Oncology,
Health,
Clinical Trials,
Lung cancer,
Ovarian cancer,
B cell,
Metastasis,
Patient,
City,
CIRM,
Virus,
Cancer,
Clinical trial,
Supernova,
Immune system,
Patent,
Dove Medical Press Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today reported its fourth quarter and full-year 2023 operating and financial results and reviewed recent business highlights.
Key Points:
- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today reported its fourth quarter and full-year 2023 operating and financial results and reviewed recent business highlights.
- “Calidi continues to make great progress across our development programs while continuing to innovate and expand our industry-leading position in cell-based immunotherapies,” said Allan Camaisa, CEO and Chairman of the Board of Calidi Biotherapeutics.
- Publicly announced novel systemic enveloped oncolytic virotherapy program, RTNova (CLD-400), targeting advanced solid tumors, including advanced metastatic disease.
- General and administrative expenses were $16.0 million for the year ended December 31, 2023, compared to $15.9 million for the year ended December 31, 2022, respectively.
Science,
Stem Cells,
Biotechnology,
Research,
Pharmaceutical,
Oncology,
Health,
Clinical Trials,
Ovarian cancer,
Regenerative medicine,
Patient,
City,
CIRM,
Woman,
Neoplasm,
Cancer,
Safety,
Division,
FDA,
Dove Medical Press,
NSC,
Pharmaceutical industry CLD-101 is the lead therapeutic candidate in Calidi’s NeuroNova program, comprising tumor-tropic neural stem cells (NSCs) that deliver an oncolytic adenovirus (NSC-CRAd-S-pk7) selectively to tumor sites.
Key Points:
- CLD-101 is the lead therapeutic candidate in Calidi’s NeuroNova program, comprising tumor-tropic neural stem cells (NSCs) that deliver an oncolytic adenovirus (NSC-CRAd-S-pk7) selectively to tumor sites.
- This proposed CLD-101 treatment utilizes a neural stem cell line to deliver an oncolytic adenovirus directly to abdominal ovarian tumor sites.
- In this trial, CLD-101 demonstrated safety and the stimulation of an anti-tumor response, with results published in Lancet Oncology .
- Aboody has financial interest in and is a paid advisory board member for Calidi Biotherapeutics.
Retrieved on:
Monday, February 12, 2024
Oncology,
Health,
Stem Cells,
General Health,
Pharmaceutical,
Biotechnology,
Immune system,
Vaccinia,
Neoplasm,
Dove Medical Press,
Cell,
Conference,
Supernova,
Tumor microenvironment,
Patient,
Survival,
Cancer,
Vaccine Calidi's systemic enveloped virotherapy program, ImmunoNova, leverages extensive experience in utilizing cells to protect, potentiate and deliver virotherapies.
Key Points:
- Calidi's systemic enveloped virotherapy program, ImmunoNova, leverages extensive experience in utilizing cells to protect, potentiate and deliver virotherapies.
- Utilizing an engineered and enveloped vaccinia virus, ImmunoNova shows promising potential in targeting advanced metastatic disease across the body, while maintaining survival in the bloodstream.
- Preclinical models have demonstrated ImmunoNova's efficacy in transforming tumor immune microenvironments and eradicating distant and diverse tumors.
- “Calidi's groundbreaking systemic enveloped virotherapy holds immense promise in revolutionizing the treatment landscape for cancer patients with advanced solid tumors.
Oncology,
Health,
Stem Cells,
Neurology,
Research,
Science,
Biotechnology,
Virus,
Cell,
Cancer,
Distinguishing,
University,
Biologic,
Dove Medical Press,
Neuroscience,
UAB Hospital,
Emory University,
National academy,
UAB,
Glioblastoma,
Radiation therapy,
Neuro,
Nature Biotechnology,
Physician,
Birmingham School of Law,
Engineering,
Neurosurgery,
Potyvirus,
Harvard Medical School,
Supernova,
Pulmonology,
Hospital,
Bangladesh Technical Education Board,
University of Groningen,
PNAS,
Pharmaceutical industry Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies today announced the appointment of three new members to its Scientific and Medical Advisory Board.
Key Points:
- Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies today announced the appointment of three new members to its Scientific and Medical Advisory Board.
- “Calidi continues to expand our Scientific and Medical Advisory Board, adding leading physicians and scientists from the top cancer hospitals and research institutions in the United States,” said Allan Camaisa, CEO and Chairman of the Board of Calidi Biotherapeutics.
- Dr. Chiocca is a faculty member at Harvard Medical School and leads a laboratory focused on developing novel genetic therapies for malignant brain tumors.
- from the University of Tennessee and completed his residency and fellowship at UAB Hospital in Neurology and Neuro-oncology.
Retrieved on:
Wednesday, December 13, 2023
Biotechnology,
Pharmaceutical,
Oncology,
General Health,
Health,
Infectious Diseases,
Hospitals,
Clinical Trials,
NSC,
B cell,
M.D,
Research,
Safety,
NYSE,
Immune system,
City,
Northwestern University,
HGG,
Clinical trial,
IND,
SNV,
Brain tumor,
Northwest Biotherapeutics,
Supernova,
Patient,
Tumor microenvironment,
Medicine,
Neoplasm,
University,
Virus,
NNV,
Pharmaceutical industry,
Vaccine,
Boston “Our cell-based virotherapeutics are designed to target tumors directly and to help the immune system recognize and attack distant tumor sites,” said Boris R. Minev.
Key Points:
- “Our cell-based virotherapeutics are designed to target tumors directly and to help the immune system recognize and attack distant tumor sites,” said Boris R. Minev.
- Updates to be presented at the upcoming 8th Oncolytic Virotherapy Summit include:
Progress in Recurrent High Grade Glioma (HGG) Trial.
- Calidi plans to commence a Phase 1b/2 clinical trial for NeuroNova (NNV1) in collaboration with Northwestern University during the first half of 2024.
- The company’s research is focused on engineered oncolytic vaccinia virus to increase the tumor specificity and oncolytic potency with improved systemic anti-tumor immunity.
